Published in:
01-10-2015 | Original Paper
The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation
Authors:
Jelena Kornej, Gerhard Hindricks, M. Benjamin Shoemaker, Daniela Husser, Arash Arya, Philipp Sommer, Sascha Rolf, Pablo Saavedra, Arvindh Kanagasundram, S. Patrick Whalen, Jay Montgomery, Christopher R. Ellis, Dawood Darbar, Andreas Bollmann
Published in:
Clinical Research in Cardiology
|
Issue 10/2015
Login to get access
Abstract
Background
Recurrent atrial fibrillation (AF) occurs in up to 50 % of patients within 1 year after catheter ablation, and a clinical risk score to predict recurrence remains a critical unmet need. The aim of this study was to (1) develop a simple score for the prediction of rhythm outcome following catheter ablation; (2) compare it with the CHADS2 and CHA2DS2-VASc scores, and (3) validate it in an external cohort.
Methods
Rhythm outcome between 3 and 12 months after AF catheter ablation were documented. The APPLE score [one point for age >65 years, persistent AF, impaired eGFR (<60 ml/min/1.73 m2), LA diameter ≥43 mm, EF < 50 %] was associated with AF recurrence and was validated in an external cohort in 261 patients with comparable ablation and follow-up.
Results
In 1145 patients (60 ± 10 years, 65 % male, 62 % paroxysmal AF) the APPLE score showed better prediction of AF recurrences (AUC 0.634, 95 % CI 0.600–0.668, p < 0.001) than CHADS2 (AUC 0.538) and CHA2DS2-VASc (AUC 0.542). Compared to patients with an APPLE score of 0, the odds ratio for AF recurrences was 1.73, 2.79 and 4.70 for APPLE scores 1, 2, or ≥3, respectively (all p < 0.05). In the external validation cohort, the APPLE score showed similar results (AUC 0.624, 95 % CI 0.562–0.687, p < 0.001).
Conclusions
The novel APPLE score is superior to the CHADS2 and CHA2DS2-VASc scores for prediction of rhythm outcome after catheter ablation. It holds promise as a useful tool to identify patients with low, intermediate, and high risk for AF recurrence.